Table 3.
Risk of PE, DVT, CAD and CVD of AI treatment compared with TAM treatment in postmenopausal woman.
| Hazard ratio estimates | |||||
|---|---|---|---|---|---|
| Outcome | Subtype | Number of events | Unadjusted HR (95%CI) | Adjusted HR (95%CI) | |
| TEEs | PE | TAM AI |
7 93 |
1.77 (0.82–3.82) | 1.91 (0.88–4.13) |
| DVT | TAM AI |
42 252 |
0.92 (0.68–1.24) | 0.81 (0.58–1.13) | |
| CVEs | CAD | TAM AI |
32 260 |
1.02 (0.71–1.47) | 1.12 (0.77–1.62) |
| CVD | TAM AI |
1 11 |
1.02 (0.71–1.48) | 1.49 (0.19–11.66) | |
| Competing risk estimates | |||||
| Outcome | Subtype | Number of events | Unadjusted SHR (95%CI) | Adjusted SHR (95%CI) | |
| TEEs | PE | TAM AI |
7 93 |
1.91 (0.88–4.12) | 2.15 (0.99–4.64) |
| DVT | TAM AI |
42 252 |
0.84 (0.61–1.17) | 0.89 (0.64–1.24) | |
| CVEs | CAD | TAM AI |
32 260 |
1.12 (0.77–1.61) | 1.29 (0.89–1.87) |
| CVD | TAM AI |
1 11 |
1.52 (0.20–11.76) | 1.75 (0.22–13.71) | |
Adjusted results were obtained using continuous PS estimates.
AI, aromatase inhibitors; CAD, coronary artery disease; CI, confidence interval; CVD, cerebrovascular diseases, including stroke and intracerebral hemorrhage; CVEs, cardiovascular events; DVT, deep vein thrombosis, phlebitis and thrombophlebitis; HR, hazard ratio; PE, pulmonary embolism; PS, propensity score; SHR, subdistribution hazard ratio; TAM, tamoxifen; TEEs, thromboembolic events.